Skip to content


You're viewing the new version of our site. Please leave us feedback.

Learn more
Open Access

The novel NO redox sibling, nitroxyl (HNO), prevents cardiomyocyte hypertrophy and superoxide generation via cGMP

  • Rebecca Ritchie1Email author,
  • Jennifer Irvine1,
  • Swati Gossain1, 2,
  • Jane Love1,
  • John Horowitz3 and
  • Barbara Kemp-Harper2
BMC Pharmacology20099(Suppl 1):P58

Published: 11 August 2009

We have previously shown that NO/cGMP signalling is an important antihyper-trophic mechanism in the heart [13]. HNO is the one electron reduction of NO•, thought to elicit cardiovascular actions via cGMP and/or calcitonin gene-related peptide (CGRP) [4]; we have recently shown that the HNO donor Angeli's salt inhibits cardiomyocyte hypertrophy and superoxide generation [5]. We now test the hypothesis that isopropylamine/NO (IPA/NO) elicits concentration-dependent anti-hypertrophic and antioxidant actions via HNO/sGC/cGMP-dependent signalling. IPA/NO (0.1–3 μM, replenished 3×/day over 48 h) elicited concentration-dependent inhibition of endothelin-1 (ET1, 60 nM)-stimulated neonatal rat cardiomyocyte (NRCM) hypertrophy (on two dimensional area of live cells). At 3 μM, IPA/NO decreased cell size from 255 ± 28% to 96 ± 27% of paired control (n = 4, p < 0.001). This antihypertrophic action of IPA/NO was significantly attenuated in the presence of the HNO scavenger L-cysteine (3 mM) or the cGMP-dependent protein kinase inhibitor Rp-8 PCTP cGMPS (10 μM, both n = 4, p < 0.05), but was unaffected by the NO scavenger carboxy-PTIO (200 μM) or the CGRP antagonist, CGRP8–37 (1 μM, both n = 4). For comparison, the NO• donor DEA/NO elicited similar concentration-dependent inhibition of ET1-induced cardiomyocyte hypertrophy; this was inhibited by carboxy-PTIO and Rp-8 PCTP cGMPS (10 μM, both n = 4, p < 0.05), but was unaffected by L-cysteine. Both IPA/NO and DEA/NO also blocked ET1-induced cardiomyocyte superoxide generation (both n = 4, p < 0.001, on NADPH-driven lucigenin-enhanced chemiluminescence), a key trigger of hypertrophy [3]. IPA-NO stimulated purified cell-free sGC activity by 3.2 ± 0.6-fold, and elevated NRCM cGMP content by 3.5 ± 0.4-fold (both n = 5, p < 0.05 via cGMP ELISA, as previously described [2, 3]. None of these agents alone, or their respective vehicles, elicited any effect on NRCM. Finally, using an NO•-sensing electrode, we demonstrated that IPA/NO (in contrast to DEA/NO), does not release NO• under these conditions, even at supra-pharmacological concentrations. In conclusion, these results provide convincing evidence that IPA/NO prevents cardiomyocyte hypertrophy via HNO activation of sGC. Although the antihypertrophic and antioxidant efficacy of IPA/NO was comparable to NO•, there is no role for extracellular oxidation of HNO to NO• or CGRP-mediated signalling in these IPA/NO actions. These studies may ultimately facilitate the development of HNO donors such as IPA/NO as novel antihypertrophic therapy for patients at risk of heart failure.

Authors’ Affiliations

Heart Failure Pharmacology, Baker IDI Heart & Diabetes Institute
Department of Pharmacology, Monash University
Cardiology Unit, The Queen Elizabeth Hospital


  1. Rosenkranz AC, Hood SG, Woods RL, Dusting GJ, Ritchie RH: Acute antihypertrophic actions of bradykinin in the rat heart: importance of cyclic GMP. Hypertension. 2002, 40: 498-503. 10.1161/01.HYP.0000032854.74042.CF.View ArticlePubMedGoogle Scholar
  2. Rosenkranz AC, Dusting GJ, Woods RL, Ritchie RH: Antihypertrophic actions of the natriuretic peptides in adult rat cardiomyocytes: importance of cyclic GMP. Cardiovasc Res. 2003, 57: 515-522. 10.1016/S0008-6363(02)00667-3.View ArticlePubMedGoogle Scholar
  3. Laskowski AC, Woodman OL, Cao AH, Drummond GR, Marshall T, Kaye DM, Ritchie RH: Antioxidant actions contribute to the antihypertrophic effects of ANP in neonatal rat cardiomyocytes. Cardiovasc Res. 2006, 72: 112-123. 10.1016/j.cardiores.2006.07.006.View ArticlePubMedGoogle Scholar
  4. Irvine JC, Ritchie RH, Favaloro JL, Andrews KL, Widdop RE, Kemp-Harper BK: Invited Review: Nitroxyl (HNO): The Cinderella of the Nitric Oxide Story. Trends Pharmacol Sci. 2008, 29: 601-608. 10.1016/ ArticlePubMedGoogle Scholar
  5. Ritchie RH, Lin EQ, Cao AH, Patel R, Kaye DM, Kemp-Harper BK: The NO redox sibling, nitroxyl (HNO), blocks cardiomyocyte hypertrophy via suppression of NADPH oxidase. Circulation. 2007, 116 (Suppl II): 19-II_20.Google Scholar


© Ritchie et al; licensee BioMed Central Ltd. 2009

This article is published under license to BioMed Central Ltd.